Ronglan Zhao
Overview
Explore the profile of Ronglan Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu Q, Peng X, Xu G, Bai X, Cao Y, Du Y, et al.
Eur J Pharmacol
. 2025 Feb;
995:177421.
PMID: 39993700
Studies have indicated that P2X7 receptor are involved in the progression of non-small cell lung cancer (NSCLC). Therefore, this study sought to explore how modulating P2X7 receptor expression levels affect...
2.
Wang X, Peng X, Cao Y, Zhu X, Du Y, Yu Q, et al.
J Biochem Mol Toxicol
. 2025 Feb;
39(2):e70184.
PMID: 39967467
Purinergic ligand-gated ion channel 7 receptor (P2X7R) has essential functions in tumor proliferation, apoptosis, metastasis, and invasion, and the purpose of this study was to explore the effects of P2X7R...
3.
Cao Y, Du Y, Song W, Yu Q, Wang X, Zhao R, et al.
Curr Med Chem
. 2024 Sep;
PMID: 39252620
Lung cancer is the second malignant tumor in the world and is the most prevalent malignant tumor of the respiratory system. In lung cancer, the P2X7 receptor (P2X7R) is an...
4.
Du Y, Cao Y, Song W, Wang X, Yu Q, Peng X, et al.
Purinergic Signal
. 2024 Jul;
PMID: 39039304
Breast cancer is a common malignant tumor, whose incidence is increasing year by year, and it has become the malignant tumor with the highest incidence rate in women. Purine ligand-gated...
5.
Zhao Y, Zhang X, Ding X, Wang Y, Li Z, Zhao R, et al.
Front Pharmacol
. 2024 Jun;
15:1294668.
PMID: 38828446
FLT3 mutations are closely associated with the occurrence of hematological and solid malignancies, especially with acute myeloid leukemia. Currently, several FLT3 inhibitors are in clinical trials, and some have been...
6.
Wang X, Yu Q, Bai X, Li X, Sun Y, Peng X, et al.
Eur J Cancer Prev
. 2023 Nov;
33(3):271-281.
PMID: 37942897
The incidence of digestive malignancies has increased in recent years, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer. Advanced stages of these cancers are prone to metastasis, which...
7.
Peng X, Zhang Y, Bai X, Li X, Zhao R
Int Immunopharmacol
. 2023 May;
119:110241.
PMID: 37141671
Purinergic ligand-gated ion channel 7 receptor (P2X7R) is a purine type P2 receptor that is expressed on a variety of immune cells. Recent studies have shown that P2X7R signaling is...
8.
Yu Q, Wang X, Li X, Bai X, Zhao R, Peng X
Clin Transl Oncol
. 2023 Mar;
25(8):2297-2305.
PMID: 36856920
Pancreatic cancer is one of the deadliest types of cancer, with a death rate nearly equal to the incidence. The P2X7 receptor (P2X7R) is a kind of extracellular adenosine triphosphate...
9.
Bai X, Li Q, Peng X, Li X, Qiao C, Tang Y, et al.
Purinergic Signal
. 2023 Mar;
19(4):685-697.
PMID: 36854856
It has been demonstrated that the ATP-gated ion channel P2X7 receptor is involved in tumor progression and plays an important role in regulating tumor cell growth, invasion, migration and angiogenesis....
10.
Bai X, Li X, Qiao C, Tang Y, Zhao R, Peng X
Mol Biol Rep
. 2022 Nov;
50(2):1687-1699.
PMID: 36417079
Purinergic ligand-gated ion channel 7 receptor (P2X7R) is a nonselective cation channel of the purinergic receptor family. P2X7R is activated by adenosine triphosphate (ATP) and plays a significant role in...